BioSpace News Archive

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will host a conference call to provide a research and development (R&D) and Corporate update at 8:30 a.m. EST on December 9, 2020 . The call will include the Protagonist management team and Andrew Kuykendall , M.D., an investigator in the PTG-300

Cogent Biosciences, Inc. (“Cogent”) (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Brad Barnett as Chief Technology Officer (CTO).

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell 1,500,000 shares of its common stock.

The present research report offers comprehensive analysis of the global drug eluting balloon market for the forecast period of 2019 to 2029.

Augmented awareness about bioterrorism attacks in many of the developed countries, such as Germany and the US is likely to play an important role in the growth of the global biodefense market in the years to come.

The demand within the global transient protein expression market is expected to trace an ascending graph line in the times to follow.

Increased acceptance of viral antigens in the vaccine development is foreseen to fuel the growth of the global viral antigens market during the assessment period of 2020 to 2030.

The rise in geriatric population, their vulnerability towards various diseases of the backbone and spinal cord is a prime factor aiding in expansion of the global polyether ether ketone interbody devices market.

The over-the-counter pain medication market is predicted to display notable growth over the forecast period from 2020 to 2030.

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization of mammalian, microbial biologics and gene therapy plasmid DNA, announces a new agreement with Nature Technology Corporation for use of NTC’s proprietary HyperGRO™ manufacturing platform.